AHSG and metabolic dysfunction-associated steatotic liver disease: More analytically, we have three main findings: (a) NAFLD is highly prevalent among all patients with definite atherosclerotic disease, though the highest prevalence rates are found among those patients with PAD; (b) despite a lower prevalence of NAFLD, patients with CAD have higher values of Fetuin-A than patients with PAD; (c) Fetuin-A is positively associated with NAFLD in CAD patients.